Literature DB >> 32978648

"Real world" clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients.

Vincent Ferraro1, Simon Lafrenière2, Marie-France Demers3, Marc-André Roy4, Amal Abdel-Baki5.   

Abstract

Entities:  

Year:  2020        PMID： 32978648     DOI： 10.1007/s00213-020-05656-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  3 in total

1.  Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program.

Authors:  Amal Abdel-Baki; Clairélaine Ouellet-Plamondon; Émilie Salvat; Kawthar Grar; Stéphane Potvin
Journal:  Psychiatry Res       Date:  2016-11-10       Impact factor: 3.222

2.  Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.

Authors:  Kenneth L Subotnik; Laurie R Casaus; Joseph Ventura; John S Luo; Gerhard S Hellemann; Denise Gretchen-Doorly; Stephen Marder; Keith H Nuechterlein
Journal:  JAMA Psychiatry       Date:  2015-08       Impact factor: 21.596

3.  Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.

Authors:  Adam J Savitz; Haiyan Xu; Srihari Gopal; Isaac Nuamah; Paulien Ravenstijn; Adam Janik; Alain Schotte; David Hough; Wolfgang W Fleischhacker
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.